scholarly journals Re: Does Prescription Opioid Misuse Affect the Level of Health Care Satisfaction Endorsed by Patients on Opioid Therapy?

2020 ◽  
Vol 33 (3) ◽  
pp. 484-484
Author(s):  
Ayodeji Otufowora
2019 ◽  
Vol 15 (4) ◽  
pp. 323-331
Author(s):  
Wally R. Smith, MD ◽  
Donna K. McClish, PhD ◽  
John D. Roberts, MD ◽  
Osama Kandalaft, MD ◽  
Bassam Dahman, PhD ◽  
...  

Objective: To develop a survey instrument to identify adult sickle cell disease (SCD) patients on chronic opioid therapy who are at-risk for opioid abuse. Design: Prospective survey and interview.Setting: Adult SCD clinic in a large urban teaching facility.Patients/participants: Convenience sampling of adult patients presenting to the sickle cell clinic.Interventions: None.Main outcome: Primary outcome was “at-risk for opioid misuse,” defined as at least 3/8 “yes” answers (a positive composite score) on the Prescription Opioid Misuse Index (POMI) questionnaire. Secondary outcome was DSM-IV criteria for substance abuse using the DSM IV Diagnostic Interview Schedule.Results: Of the 99 patients who completed the POMI, the mean age was 36 years; 58.6 percent were female, 48 percent were hemoglobin SS (47/99), and 26 percent were SC (26/99). Twenty-four percent (24/99) were identified as at-risk for opioid misuse using the POMI. There were no differences in demographic, SCD genotype, or socioeconomic variables for at-risk versus not-at-risk patients.Conclusion: Twenty-four percent of unselected adult SCD patients on opioids were identified as at-risk for opioid misuse using a quick survey. This may represent as much as 2.5-7 times the national misuse rate. This group of patients may benefit from additional diagnostic and therapeutic interventions to help understand and manage their opioid usage.


2012 ◽  
Vol 10 (4) ◽  
pp. 304-311 ◽  
Author(s):  
A. Grattan ◽  
M. D. Sullivan ◽  
K. W. Saunders ◽  
C. I. Campbell ◽  
M. R. Von Korff

2015 ◽  
Vol 11 (1) ◽  
Author(s):  
Benjamin J. Morasco, PhD ◽  
Erin E. Krebs, MD, MPH ◽  
Renee Cavanagh, MS ◽  
Stephanie Hyde, MA ◽  
Aysha Crain, MSW ◽  
...  

Background/objective: Urine drug testing (UDT) may be used to help screen for prescription opioid misuse. There are little data available describing usual pain care practices for patients who have aberrant UDT results. The goal of this research was to evaluate the clinical care for patients prescribed chronic opioid therapy (COT) and have an aberrant UDT.Design: Retrospective cohort study.Setting: VA Medical Center in the Pacific Northwest.Participants: Patients with chronic pain who were prescribed COT and had a UDT result that was positive for an illicit or nonprescribed substance.Main outcome measures: This was an exploratory study designed to document usual care practices.Results: Participants' (n = 83) mean age was 49.5 (SD = 9.6) and 81.5 percent were male. The most common substances detected on UDT were marijuana (69 percent) or a nonprescribed opioid (25 percent); 18 percent had a UDT positive for two or more substances. Plans to modify treatment were documented in 69 percent of cases. The most common treatment change after aberrant UDT results was instituting more frequent UDTs, which occurred in 43 percent of cases. Clinicians documented plans to alter their opioid prescribing (eg, terminating opioids, requiring more frequent fills, changing opioid dose, or transitioning to another opioid) in 52 percent of cases, but implemented these changes in only 24 percent.Discussion: Current methods for optimizing treatment after obtaining aberrant UDT results should be enhanced. To improve the utility of UDT to reduce prescription opioid misuse, additional interventions and support for clinicians need to be developed and tested.


Medical Care ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Katarina A. Ferrucci ◽  
Tubanji Walubita ◽  
Ariel L. Beccia ◽  
Eric Y. Ding ◽  
Bill M. Jesdale ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document